A Randomized, Single-blind, Placebo-controlled Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN RSV Vaccine in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Feb 2017
At a glance
- Drugs MVA-BN RSV (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors Bavarian Nordic
- 23 Feb 2017 Six month follow-up data published in a Bavarian Nordic media release.
- 29 Sep 2016 Results published in Bavarian Nordic media release.
- 29 Sep 2016 According to Bavarian Nordic media release, data from this trial presented at the 10th International Respiratory Syncytial Virus Symposium.